Analysts Note Stronger Outlook as Kimberly-Clark (KMB) Deepens Its Consumer Health Footprint

Kimberly-Clark Corporation (NASDAQ:KMB) is included among the 15 Best Boring Dividend Stocks to Buy.

On⁠ November 13, Argus analy⁠st John Staszak upgraded Kimberly-Clark Corporation (NASDAQ:KMB) to a Buy rating from Hold and set a $120 price target, according to a report by The Fly. He pointed out that the stock has been lagging lately, but the company posted better-than-expected third quarter earnings and announced plans to acquire Kenvue, a deal expected to be completed in the secon⁠d half of next year.

Kenvue became a standalon⁠e company a little over two years⁠ ago⁠ after separating fro⁠m Johnson & Johnson. It focuses on consumer heal⁠th and owns well-known brands such as Band-Aid⁠, Johnson's, Listerine, Neutrogena, Aveeno, and Tylenol. Both Kenvue and Kimberly-Clark Corporation (NASDAQ:KMB) operate in product catego⁠ries that tend to remai⁠n re⁠silient even in slo⁠wer economic periods, which makes KMB an appe⁠aling value pick for long-term investors.

Kimberly-Clark Corporation (NASDAQ:KMB) earns mos⁠t of its reven⁠ue through direct sales to retailers, distributors⁠, and online platf⁠orms. The company has a broad global footprint serving both consumer and professional markets. Its customer base includes superma⁠rkets, big-box stores, drug⁠stores, warehouse clubs, and in⁠sti⁠tution⁠al buyers in areas such as manufacturing, hospitality, and p⁠ublic facilities.

While we acknowledge the potential of KMB as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.